ReviewNeuro-oncology2012
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.
Review in Neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer.Stem cell research & therapy · 2026Article
- CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.Journal for immunotherapy of cancer · 2023Article
- Human neural stem cells repress glioma cell progression in a paracrine manner by downregulating the Wnt/β-catenin signalling pathway.FEBS open bio · 2023Article
- Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial.Journal of translational medicine · 2023Article
- Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies.International journal of molecular sciences · 2022Review
- Reporter Genes for Brain Imaging Using MRI, SPECT and PET.International journal of molecular sciences · 2022Review
- Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model.Journal for immunotherapy of cancer · 2020Article
- Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection.Nanotechnology · 2018Article
- Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?Journal of experimental & clinical cancer research : CR · 2017Article
- Cancer therapy: Neutrophils traffic in cancer nanodrugs.Nature nanotechnology · 2017Article
- VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.Neuro-oncology · 2017Article
- Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications.Stem cells international · 2016Review
- Monitoring the Bystander Killing Effect of Human Multipotent Stem Cells for Treatment of Malignant Brain Tumors.Stem cells international · 2016Article
- Assessment of bystander killing-mediated therapy of malignant brain tumors using a multimodal imaging approach.Stem cell research & therapy · 2015Article
- Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.Drug design, development and therapy · 2015Review
- Stem cells and gliomas: past, present, and future.Journal of neuro-oncology · 2014Review
- Stem cell delivery of therapies for brain disorders.Clinical and translational medicine · 2014Review
- Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Journal of cancer research & therapy · 2014Article
- Strategies in gene therapy for glioblastoma.Cancers · 2013Article
- Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo.Neural regeneration research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Stem cells have generated great interest in the past decade as potential tools for cell-based treatment of human high-grade gliomas. Thus far, 3 types of stem cells have been tested as vehicles for various therapeutic agents: embryonic, neural, and mesenchymal. The types of therapeutic approaches and/or agents examined in the context of stem cell-based delivery include cytokines, enzyme/prodrug suicide combinations, viral particles, matrix metalloproteinases, and antibodies. Each strategy has specific advantages and disadvantages. Irrespective of the source and/or type of stem cell, there are several areas of concern for their translation to the clinical setting, such as migration in the adult human brain, potential teratogenesis, immune rejection, and regulatory and ethical issues. Nonetheless, a clinical trial is under way using neural stem cell-based delivery of an enzyme/prodrug suicide combination for recurrent high-grade glioma. A proposed future direction could encompass the use of stem cells as vehicles for delivery of agents targeting glioma stem cells, which have been implicated in the resistance of high-grade glioma to treatment. Overall, stem cells are providing an unprecedented opportunity for cell-based approaches in the treatment of high-grade gliomas, which have a persistently dismal prognosis and mandate a continued search for therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.